Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + pembrolizumab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Venetoclax + pembrolizumab is a combination regimen under investigation for cancer therapy. **Venetoclax** is a small molecule inhibitor targeting BCL-2, a protein that suppresses apoptosis and is overexpressed in several hematological and solid tumors, thereby restoring programmed cell death in malignant cells[2][4][6]. **Pembrolizumab** is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor of the PD-1 receptor, blocking its interaction with ligands (PD-L1/PD-L2) and augmenting anti-tumor T-cell immune responses. The combination is being explored for synergistic antitumor activity in indications such as non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML), with ongoing early-phase trials for patients with high PD-L1 expression in NSCLC[1], and also studied as part of triplet regimens in AML[5][3].
- Other names
- venetoclax + pembrolizumab
02
Targets
BCL-2 (BCL-2 family)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on venetoclax + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + pembrolizumab.